Navigation Links
Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting

immunomodulatory activities without replicating its side effects. In phase 2 clinical trials, CRx-102 demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis and was generally well tolerated. CRx-102 is being developed in a modified-release commercial formulation for the treatment of multiple immuno-inflammatory diseases.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its strategic development, its product candidates and their clinical potential, its plans for clinical and formulation development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candid
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
Post Your Comments:
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... 2014 The federal judge overseeing ... http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. has ... selected for one of the proceeding’s bellwether trials. ... 2014, U.S. District Judge Joseph R. Goodwin of ... Boston Scientific’s contention that a consolidated trial would ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:8/30/2014)... 2014 Top10BestSEOHosting.com is a well-known ... announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the ... Also, they has announced that Bluehost and Arvixe ... Hostgator, one of the Top 10 Web Hosting ... Windows hosting, and it offers rich features and ...
(Date:8/30/2014)... August 30, 2014 August 28th, 2014: ... pain in our society and the toll that takes ... it’s vital that continuing education for physical therapists addresses ... help physical therapists help others, Hands-On Seminars is offering ... , Three learning styles are available to fit ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... causes bloodstream infections is five times more lethal than other ... potent antibiotic drug vancomycin used to treat MRSA, according to ... 50 percent of the patients infected with the strain died ... with other MRSA strains. The average 30-day mortality ...
... During Last Year,s ,One Million Tests, World AIDS Day ... Testing Goal by Testing 35,034 , PHNOM PENH, Cambodia, ... to test several million people for HIV in observance of ... 2009 campaign, AHF/Cambodia CARES will launch its inaugural testing effort ...
... most seriously ill, experts say , SATURDAY, Oct. 31 (HealthDay ... to double the risk of stroke in patients with diabetes ... a new study finds. , Darbepoetin alfa, marketed as ... prescribed for diabetic patients with chronic kidney disease and mild ...
... Amgen (Nasdaq: AMGN ) today announced the ... Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, ... kidney disease (CKD) not on dialysis, moderate anemia and ... New England Journal of Medicine and presented ...
... Long Beach, CA; December 8, 2009 , NEEDHAM, ... announced that a special event, Terminology Services Information Day, will ... CA USA on December 8, 2009. For more information and ... http://www.omg.org/terminology-services-day . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090629/DC39325LOGO ...
... based in McAllen, Texas, has agreed to pay the United ... False Claims Act, the Anti-Kickback Statute and the Stark Statute ... in order to induce them to refer patients to hospitals ... L.P., d/b/a/ South Texas Health System, is a subsidiary of ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:OMG Announces Special Event: Terminology Services Information Day 2Health News:OMG Announces Special Event: Terminology Services Information Day 3Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 2Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 3
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... The Precisionist workstation is a ... operating system allowing infinite flexibility for ... to meet the demands of changing ... A new concept in ophthalmic surgical ...
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: